IQVIA (NYSE:IQV) PT Lowered to $279.00 at JPMorgan Chase & Co.

IQVIA (NYSE:IQV) had its price target cut by JPMorgan Chase & Co. from $288.00 to $279.00 in a research note published on Wednesday, Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Several other analysts also recently weighed in on the stock. Truist Financial decreased their price target on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Royal Bank of Canada began coverage on IQVIA in a research report on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price target on the stock. Evercore ISI decreased their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Robert W. Baird boosted their price target on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a report on Friday, September 20th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $267.27.

IQVIA Stock Up 1.4 %

NYSE:IQV opened at $214.63 on Wednesday. The company has a market cap of $39.11 billion, a price-to-earnings ratio of 29.32, a price-to-earnings-growth ratio of 2.22 and a beta of 1.49. IQVIA has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a fifty day simple moving average of $238.13 and a 200-day simple moving average of $230.78.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently made changes to their positions in IQV. Versant Capital Management Inc lifted its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new stake in IQVIA in the second quarter valued at approximately $27,000. Park Place Capital Corp acquired a new position in IQVIA in the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. acquired a new stake in IQVIA during the 2nd quarter valued at approximately $29,000. Finally, Riverview Trust Co purchased a new stake in shares of IQVIA in the 1st quarter valued at $32,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.